Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen other Products (Segment Note 2 Aggregate) — Rest of World (ROW) product sales ($M) ($M)
Form 10-Q / 10-K Note 2 & MD&A Other Product Sales by Geographic Region
Latest, Q2 2026
414
Period ended Jun 30, 2026
Change on a year earlier
+6.2%
390 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
33
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other Products (Segment Note 2 Aggregate) — Rest of World (ROW) product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 414 | +6.2% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 397 | +8.5% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 543 | +39.6% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 445 | +9.9% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 390 | +0.3% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 366 | -10.7% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 389 | +14.4% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 405 | +23.1% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 389 | +5.4% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | 410 | +16.8% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 340 | -261.1% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2023 | Sep 30, 2023 | 329 | -41.2% | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2023 | Jun 30, 2023 | 369 | -35.4% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 351 | -33.0% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | -211 | +80.3% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2022 | Sep 30, 2022 | 560 | +0.5% | Form 10-Q (filed 2023-10-31) ↗ |
| Q2 2022 | Jun 30, 2022 | 571 | +1.4% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 524 | +2.1% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2021 | Dec 31, 2021 | -117 | -227.2% | Form 10-K (filed 2024-02-14) ↗ |
| Q3 2021 | Sep 30, 2021 | 557 | +8.6% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 563 | +4.3% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 513 | -14.4% | Form 10-Q (filed 2022-04-28) ↗ |
| Q4 2020 | Dec 31, 2020 | 92 | -60.9% | Form 10-K (filed 2023-02-09) ↗ |
| Q3 2020 | Sep 30, 2020 | 513 | -5.0% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 540 | +5.3% | Form 10-Q (filed 2021-08-04) ↗ |
| Q1 2020 | Mar 31, 2020 | 599 | +41.3% | Form 10-Q (filed 2021-04-28) ↗ |
| Q4 2019 | Dec 31, 2019 | 235 | -54.9% | Form 10-K (filed 2022-02-16) ↗ |
| Q3 2019 | Sep 30, 2019 | 540 | +50.0% | Form 10-Q (filed 2020-10-29) ↗ |
| Q2 2019 | Jun 30, 2019 | 513 | +46.6% | Form 10-Q (filed 2020-07-29) ↗ |
| Q1 2019 | Mar 31, 2019 | 424 | +38.6% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 521 | +35.0% | Form 10-K (filed 2021-02-09) ↗ |
| Q3 2018 | Sep 30, 2018 | 360 | -2.7% | Form 10-Q (filed 2019-10-30) ↗ |
| Q2 2018 | Jun 30, 2018 | 350 | -5.1% | Form 10-Q (filed 2019-07-31) ↗ |
| Q1 2018 | Mar 31, 2018 | 306 | -1.9% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 386 | – | Form 10-K (filed 2019-02-13) ↗ |
| Q3 2017 | Sep 30, 2017 | 370 | – | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2017 | Jun 30, 2017 | 369 | – | Form 10-Q (filed 2018-07-27) ↗ |
| Q1 2017 | Mar 31, 2017 | 312 | – | Form 10-Q (filed 2018-04-25) ↗ |
Cite this data
StockData. (2026). Amgen Other Products (Segment Note 2 Aggregate) — Rest of World (ROW) product sales ($M) ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_other_row
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.